Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
ConditionKaposiform Hemangioendothelioma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorWest China Hospital
About this trial
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Eligibility criteria
Qualifiers
KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.
With evaluable clinical or imaging parameters to monitor disease activity or recurrence.
Patients or their guardians are able to understand the study and provide written informed consent.
Hematologic and hepatic/renal function meet the safety criteria for drug administration.
Disqualifiers
Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.
Trial design
Treatments tested in this trial
- Sirolimus
Treatment groups
120 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov